A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Public ClinicalTrials.gov record NCT02773030. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Study identification
- NCT ID
- NCT02773030
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 466 participants
Conditions and interventions
Conditions
Interventions
- CC-220 Drug
- Dexamethasone Drug
- Daratumumab Drug
- Bortezomib Drug
- Carfilzomib Drug
- Daratumumab - 16mg/kg Drug
- Bortezomib (BTZ) Drug
- Daratumumab- 1800mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 14, 2016 (Actual)
- Primary completion
- May 9, 2024 (Actual)
- Completion
- Jul 28, 2028 (Estimated)
- Last update posted
- Mar 20, 2026
2016 – 2028
United States locations
- U.S. sites
- 58
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 102 | Scottsdale | Arizona | 85259 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Local Institution - 107 | Little Rock | Arkansas | 72205 | — |
| University of Arkansas for Medical Sciences | Little Rock | Arkansas | 72205 | — |
| Local Institution - 101 | Atlanta | Georgia | 30322 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Local Institution - 120 | Chicago | Illinois | 60611 | — |
| Robert H Lurie Comprehensive Cancer Center NW Univ | Chicago | Illinois | 60611 | — |
| Local Institution - 113 | Fairway | Kansas | 66205 | — |
| University of Kansas Cancer Center | Fairway | Kansas | 66205 | — |
| Local Institution - 106 | Baltimore | Maryland | 21201 | — |
| University of Maryland School of Med | Baltimore | Maryland | 21201 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | — |
| Local Institution - 114 | Boston | Massachusetts | 02115 | — |
| Local Institution - 115 | Boston | Massachusetts | 02117 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02117 | — |
| Dana-Farber/Mass General Brigham Cancer Care, Inc | Boston | Massachusetts | 02215 | — |
| Local Institution - 110 | Boston | Massachusetts | 02215 | — |
| Local Institution - 104 | Ann Arbor | Michigan | 48109 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Local Institution - 103 | Detroit | Michigan | 48201 | — |
| Local Institution - 140 | Grand Island | Nebraska | 68803 | — |
| Local Institution - 141 | Grand Island | Nebraska | 68803 | — |
| Local Institution - 137 | Omaha | Nebraska | 68114 | — |
| Local Institution - 138 | Omaha | Nebraska | 68124 | — |
| Local Institution - 131 | Omaha | Nebraska | 68130 | — |
| Local Institution - 139 | Papillion | Nebraska | 68046 | — |
| Local Institution - 756 | Cherry Hill | New Jersey | 08003 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Local Institution - 108 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 122 | Mineola | New York | 11501 | — |
| NYU Winthrop Hospital | Mineola | New York | 11501 | — |
| Local Institution - 121 | New York | New York | 10016 | — |
| New York University School of Medicine | New York | New York | 10016 | — |
| Icahn School of Medicine at Mount Sinai Medical Center | New York | New York | 10029 | — |
| Local Institution - 109 | New York | New York | 10029 | — |
| Local Institution - 111 | New York | New York | 10065 | — |
| New York Presbyterian Hospital Weil Cornell Medical College | New York | New York | 10065 | — |
| Local Institution - 125 | Rochester | New York | 14642 | — |
| University of Rochester Cancer Center | Rochester | New York | 14642 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Local Institution - 112 | Charlotte | North Carolina | 28204 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Local Institution - 117 | Cleveland | Ohio | 44195 | — |
| Local Institution - 124 | Columbus | Ohio | 43210 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| Local Institution - 116 | Philadelphia | Pennsylvania | 19104 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 123 | Greenville | South Carolina | 29605 | — |
| Prisma Health Cancer Institute | Greenville | South Carolina | 29605 | — |
| Local Institution - 134 | Memphis | Tennessee | 38120 | — |
| Local Institution - 118 | Dallas | Texas | 75390 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Huntsman Cancer Institute at the University of Utah | Salt Lake City | Utah | 84112-5550 | — |
| Local Institution - 119 | Salt Lake City | Utah | 84112-5550 | — |
| Local Institution - 126 | Seattle | Washington | 98109 | — |
| Local Institution - 132 | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02773030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02773030 live on ClinicalTrials.gov.